Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00581113 · ClinicalTrials.gov registry record · Phase 3

Neural Stem Cell Preserving Brain Radiation Therapy & Stereotactic Radiosurgery in Patients With 1-6 Brain Metastases

A Phase 3 study, sponsored by Virginia Commonwealth University.

Terminated
Registry status
Phase 3
Development phase
8
Enrollment target

NCT00581113 is a Phase 3 study that was terminated before completion, run by Virginia Commonwealth University. The registered enrollment target is 8 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00581113, a Phase 3 study, was terminated before completion, sponsored by Virginia Commonwealth University.

TERMINATED
Registry status
Phase 3
Development phase
8 participants
Enrollment target

Study Summary

For patients with 1-6 intraparenchymal brain metastases from various primary histologies (except for melanoma), stereotactic radiosurgery (administered upfront or concurrently) or complete surgical resection with neural stem cell (NSC)-preserving whole-brain radiotherapy (WBRT) results in improved neurocognitive profile over standard WBRT. The goal of this study is to assess feasibility of this treatment approach.

Interventions

  • RADIATION Radiotherapy

Trial Details

FieldValue
Enrollment Target 8 participants
Start Date 2007-03
Est. Completion 2009-06
Phase Phase 3

Sponsor

Virginia Commonwealth University

558 total trials

What the Registry Record Tells You About NCT00581113

The ClinicalTrials.gov registry entry for NCT00581113 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 8 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Virginia Commonwealth University, which has 558 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 1 intervention - of which Radiotherapy is the first listed.

NCT00581113 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT00581113 about?

NCT00581113 is a clinical study titled "Neural Stem Cell Preserving Brain Radiation Therapy & Stereotactic Radiosurgery in Patients With 1-6 Brain Metastases". For patients with 1-6 intraparenchymal brain metastases from various primary histologies (except for melanoma), stereotactic radiosurgery (administered upfront or concurrently) or complete surgical resection with neural stem cell (NSC)-preserving whole-brain radiotherapy (WBRT) results in improved n...

What is the current status of trial NCT00581113?

This trial is currently terminated. It is a Phase 3 study. The enrollment target is 8 participants. The study started on 2007-03. Estimated completion is 2009-06.

What interventions are being tested in trial NCT00581113?

The interventions under investigation include: Radiotherapy (RADIATION).

Who is sponsoring clinical trial NCT00581113?

This trial is sponsored by Virginia Commonwealth University, which has 558 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.